Titre : Vinblastine

Vinblastine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Radiosurgery
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vinblastine : Questions médicales les plus fréquentes", "headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-10", "dateModified": "2025-05-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vinblastine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vinblastine", "alternateName": "Vinblastine", "code": { "@type": "MedicalCode", "code": "D014747", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Christine Chevreau", "url": "https://questionsmedicales.fr/author/Christine%20Chevreau", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Oncopole, Toulouse, France." } }, { "@type": "Person", "name": "Stéphane Culine", "url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr." } }, { "@type": "Person", "name": "Gwenaelle Gravis", "url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France." } }, { "@type": "Person", "name": "Florence Joly", "url": "https://questionsmedicales.fr/author/Florence%20Joly", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Arteriovenous Malformation.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37245668", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.wneu.2023.05.075" } }, { "@type": "ScholarlyArticle", "name": "Single-session stereotactic radiosurgery for large perioptic meningiomas.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36807115", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3171/2023.1.JNS221951" } }, { "@type": "ScholarlyArticle", "name": "The role of stereotactic radiosurgery in the multidisciplinary management of pituitary metastases.", "datePublished": "2022-10-06", "url": "https://questionsmedicales.fr/article/36203008", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11102-022-01279-z" } }, { "@type": "ScholarlyArticle", "name": "An empirical approach to the definition of the target margins in eye radiosurgery.", "datePublished": "2023-07-03", "url": "https://questionsmedicales.fr/article/37401002", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/acm2.13982" } }, { "@type": "ScholarlyArticle", "name": "Contemporary radiotherapy and radiosurgery techniques for refractory pituitary adenomas.", "datePublished": "2023-02-17", "url": "https://questionsmedicales.fr/article/36800067", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11102-023-01300-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vinblastine", "item": "https://questionsmedicales.fr/mesh/D014747" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vinblastine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vinblastine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vinblastine", "description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Radiosurgery&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vinblastine", "description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Radiosurgery&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vinblastine", "description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Radiosurgery&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vinblastine", "description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Radiosurgery&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vinblastine", "description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Radiosurgery&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vinblastine", "description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Radiosurgery&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vinblastine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la vinblastine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux." } }, { "@type": "Question", "name": "La vinblastine provoque-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vinblastine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine." } }, { "@type": "Question", "name": "Dans quels types de cancer la vinblastine est-elle utilisée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule." } }, { "@type": "Question", "name": "Comment la vinblastine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vinblastine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des saignements et des problèmes neurologiques." } }, { "@type": "Question", "name": "La vinblastine peut-elle affecter la moelle osseuse ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables avec la vinblastine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru." } }, { "@type": "Question", "name": "Les enfants peuvent-ils prendre de la vinblastine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance." } } ] } ] }

Sources (1684 au total)

Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Arteriovenous Malformation.

The best management for AVM, particularly high-grade ones and those that have been ruptured before, is still unknown. Data from prospective data lacks support for the best approach.... We retrospectively review patients with AVM at a single institution that were treated with radiation or a combination of radiation and embolization. These patients were divided into two groups based o... One-hundred and thirty-five (135) patients were first assessed and 121 met study criteria. Mean age at treatment was 30.5 years, and most patients were male. The groups were otherwise balanced, except... Stereotactic radiosurgery plays an important role on the treatment of AVM. Whenever possible, SRS should be preferred. Data from prospective trials about larger and previously ruptured lesions are nee...

Single-session stereotactic radiosurgery for large perioptic meningiomas.

Meningiomas close to the optic pathway are commonly candidates for microsurgical decompression, more so if they are large perioptic meningiomas. However, microsurgery itself imposes risk to vision, an... This retrospective study included 175 patients with large perioptic benign meningiomas (≥ 10 cm3) who were treated by single-session SRS. Perioptic meningiomas were defined as meningiomas touching, co... The median follow-up period was 72 months (range 13-217 months, IQR 65 months). The tumor control rate was 92%. The progression-free survival rates at 5 and 10 years were 97% and 80%, respectively. Fa... SRS provides an effective and safe treatment option for large perioptic meningiomas....

The role of stereotactic radiosurgery in the multidisciplinary management of pituitary metastases.

This study evaluates the role and outcomes of Gamma Knife radiosurgery (GKRS) in the management of pituitary metastases.... The records of brain metastases patients who underwent GKRS at the University of Pittsburgh Medical Center during the 10-year interval of 2010-2020 were systematically reviewed. Outcome measures inclu... Eighteen patients with pituitary metastases (eight male; median age of 65.5 years) had sufficient clinical follow-up for analysis. The most common primary cancers were non-small cell lung cancer (n = ... GKRS is an effective treatment modality for the multidisciplinary management of patients with pituitary metastases. This minimally-invasive strategy is associated with optimal tumor control rate and l...

An empirical approach to the definition of the target margins in eye radiosurgery.

A system for stabilizing and monitoring eye movements during LINAC-based photon beam one single fraction stereotactic radiotherapy was developed at our Institution. This study aimed to describe the fe... Our system consisted of a customized thermoplastic mask to immobilize the head, a gaze fixation LED, and a digital micro-camera. The localization procedure, which required the active collaboration of ... Twenty patients were treated with stereotactic radiosurgery (27 Gy in one fraction) for primary uveal melanoma. All patients showed a good tolerance to the treatment; until now, all patients were in l... This study showed that this noninvasive technique, based on eye position control, is appropriate and can contribute to the success of LINAC-based stereotactic radiotherapy. A millimetric safety margin...

Linac-based stereotactic radiosurgery for brain arteriovenous malformations.

Linac stereotactic radiosurgery (SRS) is gaining popularity as a form of radiation treatment for cerebral arteriovenous malformations (AVMs) since the theory of combined radiosurgical and endovascular... From a statistical record of 71 patients, 31 had partial embolisation, five surgery and 29 had no prior treatment. Using Kaplan-Meier survival and life table analyses, actuarial obliteration and annua... After a follow up of 1, 2 and 3 years the actual obliteration rates were 22, 59 and 66%, respectively whereby it was noted that prior embolization had no effect on the obliteration rate. Annual bleedi... SRS is a therapeutic option for intracerebral AVM. In general, there is a low rate of morbidity and a high probability of nidus obliteration....

Outcomes of radiation-induced meningiomas treated with stereotactic radiosurgery.

Data on the efficacy and safety of stereotactic radiosurgery (SRS) for treatment of radiation-induced meningiomas (RIMs) are limited.... A single institution database of Cobalt-60 SRS cases from 08/1999 to 10/2020 was reviewed. Radiation-induced meningiomas were identified using Cahan's criteria. Endpoints included overall survival (OS... A total of 29 patients with 86 RIM lesions were identified. Median follow-up after SRS was 59 months. The median dose prescribed to the 50% isodose line was 14 Gy (range 12-20 Gy). The actuarial 5-yr ... Stereotactic radiosurgery is a safe and effective treatment option for radiographic RIMs, WHO grade I RIMs, or lesions treated in the upfront setting. WHO grade II lesions and recurrent lesions are at...

Gamma Knife radiosurgery for meningiomas of the confluence of the falx and tentorium.

Meningiomas arising from the confluence of the falx and tentorium (CFT) are a rare and challenging subset of meningiomas. Gamma Knife radiosurgery (GKRS) is well-established as a safe and effective ma... We retrospectively identified 20 CFT meningiomas out of 2031 meningioma patients who underwent GKRS at our institution between 1987 and 2021. Tumor control, overall survival (OS), and complications we... The local tumor control rate (PFS) at 5 and 10-years were 100% (N=10) and 83% (N=4), respectively. Eight patients had stable tumor volumes and 11 patients had regression. One patient with a twice-oper... GKRS is a valuable therapeutic strategy for patients with newly diagnosed CFT meningiomas or progressive residual tumors after surgical resection....

Intratumoral hemorrhage in vestibular schwannomas after stereotactic radiosurgery.

Vestibular schwannomas (VSs) are benign tumors of the cerebellopontine angle that are typically managed with stereotactic radiosurgery (SRS). Intratumoral hemorrhage (ITH) of VSs is a rare occurrence ... Between 1987 and 2022, 2058 patients with VSs underwent Gamma Knife radiosurgery (GKRS) at the University of Pittsburgh Medical Center. The authors performed a review of the prospectively maintained V... A total of 1902 VS patients had sufficient clinical and imaging follow-up data. Five Koos grade III (n = 1) and IV (n = 4) VS patients developed ITH after GKRS, resulting in a cumulative incidence rat... ITH after VS radiosurgery is a rare phenomenon with a cumulative incidence rate of 0.26% in this series. Patient-tailored management in the form of observation or resection is based on patient present...

Incorporation of Brain Connectomics for Stereotactic Radiosurgery Treatment Planning.

Neurosurgeons have integrated neuroanatomy-based tractography to avoid critical structures during dose planning. However, they have yet to integrate more comprehensive connectome networks for radiosur... A young man presented with a Spetzler-Martin Grade 3 right temporal arteriovenous malformation.... As proof of concept, we incorporated connectomic networks including default mode network, optic radiation and central executive network into the Gamma Knife radiosurgical treatment planning workflow. ... We were able to incorporate connectomes into radiosurgical dose planning approaches. This allowed for dose reductions to the networks while still achieving delivery of a therapeutic dose to the target...